Analogue-based drug discovery II / / edited by Janos Fischer and C. Robin Ganellin

• Pubblicazione: Weinheim, : Wiley-VCH, c2010
• Descrizione fisica: 1 online resource (566 p.)
• Disciplina: 615.19
• Soggetto topico: Drug development; Drugs - Design
• Altri autori: FischerJanos GanellinC. R (C. Robin)
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Analogue-based Drug Discovery II; Contents; Preface; Introduction; Abbreviations; Part I: General Aspects; 1 Optimizing Drug Therapy by Analogues; 2 Standalone Drugs; 3 Application of Molecular Modeling in Analogue-Based Drug Discovery; 4 Issues for the Patenting of Analogues; Part II: Analogue Classes; 5 Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes; 6 Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction; 7 Rifamycins, Antibacterial Antibiotics and Their New Applications; 8 Monoterpenoid Indole Alkaloids, CNS and Anticancer Drugs ; 9 Anthracyclines, Optimizing Anticancer Analogues10 Paclitaxel and Epothilone Analogues, Anticancer Drugs; 11 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression; 12 Muscarinic Receptor Antagonists in the Treatment of COPD; 13 ß-Adrenoceptor Agonists and Asthma; Part III: Case Histories; 14 Liraglutide, a GLP-1 Analogue to Treat Diabetes; 15 Eplerenone: Selective Aldosterone Antagonist; 16 Clevudine, to Treat Hepatitis B Viral Infection; 17 Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 ; 18 Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV19 Lapatinib, an Anticancer Kinase Inhibitor; 20 Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia; 21 Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder; Index
• Sommario/riassunto: Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development.Of interest
• Titolo autorizzato: Analogue-based drug discovery II
• ISBN: 3-527-63212-3; 1-282-78383-1; 9786612783838; 3-527-63003-1; 3-527-63004-X
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910877334703321
• Lo trovi qui: Univ. Federico II